Skip to main content
Hong Jae Chon on Muck Rack

Hong Jae Chon

As seen in: Nature, Wiley Online Library, JAMA Oncology, The Lancet, Chinese Clinical Oncology, European Journal of Cancer
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Hong Jae

Contact Hong Jae, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Response: Reassessing the Use of Nivolumab Plus Ipilimumab After Atezolizumab Plus Bevacizumab in Advanced HCC

|
By Jung Sun Kim, Thomas Yau, Hong Jae Chon
| Wiley Online Library Verified
We sincerely thank the authors for their insightful comments [1] on our study evaluating nivolumab plus ipilimumab (Nivo/Ipi) as salvage therapy after atezolizumab plus bevacizumab (Ate/Bev) failure [2], and appreciate the opportunity to further address the important issues raised.
Open in Who Shared Issue with article?

Oral reovirus reshapes the gut microbiome and enhances antitumor immunity in colon cancer - Nature Communications

|
By Won Suk Lee, Hannah Yang Verified, Hong Jae Chon, Dong Guk Park
| Nature Verified
Abstract The route of oncolytic virotherapy is pivotal for immunotherapeutic efficacy in advanced cancers. In this preclinical study, an oncolytic reovirus (RC402) is orally administered to induce antitumor immunity. Oral reovirus treatment shows no gross toxicities and effectively suppresses multifocal tumor lesions.
Open in Who Shared Issue with article?

High Levels of Antidrug Antibodies Against Atezolizumab as a Predictive Marker for Clinical Outcomes in Patients With Hepatocellular Carcinoma-Reply

|
By Chan Kim, Hannah Yang Verified, Hong Jae Chon
| JAMA Oncology Verified
High Levels of Antidrug Antibodies Against Atezolizumab as a Predictive Marker for Clinical Outcomes in Patients With Hepatocellular Carcinoma—Reply In Reply We appreciate the comments from Shigematsu and Inamura regarding our cohort study on atezolizumab antidrug antibody (ADA).1 We would like to address their valuable comments.
Open in Who Shared Issue with article?
See all 6 articles